ATGC Co., Ltd.

2 clinical trials · Sponsor

Record	Firm	Date
Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines (NCT05623410)	ATGC Co., Ltd.	2022-10-11
A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines (NCT04281095)	ATGC Co., Ltd.	2019-11-01

Every clearance here is in the API, with alerts when new ones post.